Notice
Recent Posts
Recent Comments
Link
| 일 | 월 | 화 | 수 | 목 | 금 | 토 |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | ||
| 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| 13 | 14 | 15 | 16 | 17 | 18 | 19 |
| 20 | 21 | 22 | 23 | 24 | 25 | 26 |
| 27 | 28 | 29 | 30 |
Tags
- danuglipron
- orforglipron
- structure therapeutics
- gsbr-1290
- 비만치료제
- 자가면역질환 치료제
- GPCR
- Pegozafermin
- tern-601
- Novo Nordisk
- lilly
- 노보노디스크
- Nash
- Viking Therapeutics
- Semaglutide
- il-17 inhibitor
- glp-1 비만
- CAR-T in autoimmune
- 제약바이오
- CAR-T
- GLP-1
- Efruxifermin
- 경구용 glp-1
- 바이오스터디
- VKTX
- GLP-1 치료제
- Mash
- tirzepatide
- VK2735
- GLP-1치료제
Archives
- Today
- Total
목록2024 ada (1)
제약바이오 츄롸이츄롸이
Viking Therapeutics (NASDAQ: VKTX) - 2024 ADA 발표?
https://diabetesjournals.org/diabetes/article/73/Supplement_1/2064-LB/155758/2064-LB-Novel-Amylin-and-Calcitonin-Receptor 2064-LB: Novel Amylin and Calcitonin Receptor Coagonists Reduce Food Intake and Body Weight in RodentsAmylin analogs have been shown to significantly reduced body weight and dosage of insulin. Dual amylin and calcitonin receptor agonists (DACRAs) are the modiabetesjournals.or..
개별 스터디
2024. 6. 19. 15:00